| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514140200 | Plasma protease affecting | 41 |
| 20110112029 | LOW VISCOSITY COMPOSITIONS COMPRISING A PEGYLATED GLA-DOMAIN CONTAINING PROTEIN - The present invention relates to a method for lowering the viscosity of compositions comprising Vitamin K-dependent proteins. | 05-12-2011 |
| 20130123182 | IDENTIFICATION AND MOLECULAR CHARACTERISATION OF PROTEINS, EXPRESSED IN THE IXODES RICINUS SALIVARY GLANDS - The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the | 05-16-2013 |
| 20140073573 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE - The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds. | 03-13-2014 |
| 20140142040 | Heparin/Heparan Sulfate-Dependent Inhibitors of Activated Protein C and Uses Thereof in Treating Hemophilic Disorders - Methods for inhibiting activated protein C (APC) comprising contacting the APC with a Kunitz polypeptide in an amount effective in inhibiting the activity of APC, wherein the Kunitz polypeptide comprises six cysteine residues at positions corresponding to positions 7, 16, 32, 40, 53, and 57 in SEQ ID NO:1, a motif X | 05-22-2014 |
| 20140288000 | DUAL REACTIVITY POTENT KUNITZ INHIBITOR OF FIBRINOLYSIS - Compositions and methods are disclosed that relate to novel plasmin-inhibiting polypeptides that are structural variants of a human TFPI-2 Kunitz-type proteinase first inhibitor domain (KD1). The polypeptides are potent plasmin inhibitors and in certain embodiments have anti-fibrinolytic activity and/or decreased anti-coagulation activity relative to wild-type TFPI-2 KD1 and are not highly immunogenic. The plasmin-inhibiting polypeptides will find uses as anti-cancer agents, as antifibrinolytic agents, as protease inhibitors, and in other contexts. | 09-25-2014 |
| 20140323405 | ALPHA-1-ANTITRYPSIN COMPOSITIONS - A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described. | 10-30-2014 |
| 20140357566 | IDENTIFICATION AND MOLECULAR CHARACTERISATION OF PROTEINS, EXPRESSED IN THE IXODES RICINUS SALIVARY GLANDS - The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the | 12-04-2014 |
| 20160152689 | COMPOSITIONS AND METHODS FOR INHIBITING THROMBOGENESIS | 06-02-2016 |
| 514140300 | Factor VIIa affecting | 3 |
| 20120004176 | Liquid Composition of Factor VII Polypeptides - A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM. | 01-05-2012 |
| 20150105321 | COAGULATION FACTOR VII POLYPEPTIDES - The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment. | 04-16-2015 |
| 20160120992 | COAGULATION FACTOR VII POLYPEPTIDES - The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment. | 05-05-2016 |
| 514140400 | Factor Xa affecting | 4 |
| 20140296147 | METHODS OF TREATING OR PREVENTING BLOOD LOSS DURING SURGERY USING THE SERINE PROTEASE INHIBITOR MDCO-2010 - Methods of inhibiting, treating or preventing blood loss in a subject undergoing surgery through the administration of an effective amount of the novel serine protease inhibitor MDCO-2010 or its salts or esters are disclosed. | 10-02-2014 |
| 20150025011 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 01-22-2015 |
| 514140500 | Tissue factor pathway inhibitor (TFPI) utilizing | 2 |
| 20120028901 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound. | 02-02-2012 |
| 20140342987 | USE OF IXOLARIS, A TISSUE FACTOR INHIBITOR, FOR THE TREATMENT AND PREVENTION OF CANCER - The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits. | 11-20-2014 |
| 514140600 | Urokinase affecting | 1 |
| 20110028397 | Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders - The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers and other disorders. The invention further concerns pharmaceutical compositions, comprising inhibitors of uPA, preferably eye drops and eye ointments. The pharmaceutical compositions according to the invention preferably comprise PAI-2 protein or a derivative thereof retaining uPA-inhibiting capacity, or a tripeptide aldehyde inhibitor, preferably the D-Phe-Pro-Arg-aldehyde (Ald-1). The PAI-2 protein, used according to the invention, is preferably produced through bacterial expression, as a fusion protein. | 02-03-2011 |
| 514140700 | Thrombin affecting | 25 |
| 20110112030 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS - The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation. | 05-12-2011 |
| 20120065137 | THERAPEUTICS FOR TRAUMA INDUCED FACTOR V CONSUMPTIVE COAGULOPATHY - A process of treating trauma induced factor V consumptive coagulopathy is presented whereby a subject is administered a preparation of isolated factor V or a variant thereof. Administration of factor V surprisingly improves clot times and reduces the severity and propensity of bleeding events. | 03-15-2012 |
| 20120178693 | Cofactors for Thrombin Activation of Factor VII and Uses Thereof - The invention relates to fusion proteins that bind the enzyme thrombin and enhance the activation of the substrate Factor VII to the product Factor VIIa. The invention is also directed to polynucleotides, vectors, host cells, pharmaceutical compositions, and methods of treatment. | 07-12-2012 |
| 20120270789 | TREATMENT OF COAGULOPATHY WITH HYPERFIBRINOLYSIS - The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed. | 10-25-2012 |
| 20130040890 | LYOPHILIZATION METHODS, COMPOSITIONS, AND KITS - Method for lyophilization is provided, in particular methods for lyophilization of formulations comprising AT III. Also provided are compositions prepared by therefrom. Also provided are kits comprising the compositions and/or lyophilized products. | 02-14-2013 |
| 20130190243 | PHARMACOLOGICAL TREATMENT OF AORTIC ANEURYSM DEVELOPMENT - A method for pharmacological prevention and suppression of aortic aneurysm development is disclosed. The method comprises administering a therapeutically effective amount of recombinant thrombomodulin to a subject in need thereof. The recombinant thrombomodulin prevents formation and/or retards progression of an aortic aneurysm. | 07-25-2013 |
| 20130196916 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 08-01-2013 |
| 20130196917 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 08-01-2013 |
| 20130196918 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 08-01-2013 |
| 20130196919 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 08-01-2013 |
| 20130196920 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 08-01-2013 |
| 20130203674 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 08-08-2013 |
| 20130237482 | MEDICAMENT FOR THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF SEPSIS - A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient. | 09-12-2013 |
| 20130296245 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF - Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases. | 11-07-2013 |
| 20140107032 | Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events - Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y | 04-17-2014 |
| 20140194360 | USE OF ANTITHROMBIN IN EXTRACORPOREAL MEMBRANE OXYGENATION - In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®. | 07-10-2014 |
| 20140206617 | USE OF ANTITHROMBIN IN THE TREATMENT OF PRE-ECLAMPSIA - In one aspect, the disclosure provides methods for the treatment of pre-eclampsia and severe pre-eclampsia comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®. | 07-24-2014 |
| 20140256640 | TREATMENT OF COAGULOPATHY WITH HYPERFIBRINOLYSIS - The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed. | 09-11-2014 |
| 20140296148 | MEDICAMENT FOR THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF SEPSIS - A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient. | 10-02-2014 |
| 20150031620 | THROMBOMODULIN VARIANTS AND USE THEREOF - A pharmaceutical composition comprising an effective amount of a mutant thrombomodulin is disclosed. The mutant thrombomodulin comprises an ammo acid sequence that is at least 80% identical to SEQ ID NO: 2 and has residues corresponding to Ala | 01-29-2015 |
| 20150322133 | HIGHLY-PURIFIED SOLUBLE THROMBOMODULIN AND METHOD FOR PRODUCING SAME - Highly-purified soluble thrombomodulin which has a content of host cell-originated proteins being in a ratio of less than 10 ng of the proteins per 10,000 U of the soluble thrombomodulin, wherein the soluble thrombomodulin is produced by a transformant cell obtained by transfecting a host cell with a DNA containing a nucleotide sequence encoding the soluble thrombomodulin. | 11-12-2015 |
| 20160129115 | FORMULATIONS OF LIQUID STABLE ANTITHROMBIN - In one aspect, the invention provides liquid stable formulations of antithrombin. | 05-12-2016 |
| 20180021402 | MODULATORS OF COMPLEMENT ACTIVITY | 01-25-2018 |
| 514140800 | Hirudin or derivative utilizing | 2 |
| 20110015129 | NEW PAEDIATRIC INDICATIONS FOR DIRECT THROMBIN INHIBITORS - The invention relates to new paediatric indications for direct thrombin inhibitors such as dabigatran etexilate. | 01-20-2011 |
| 20120264692 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 10-18-2012 |
